Page 24 - Sun Pharma

SPARC back in the black in Q1, reports profit of Rs 57 cr; stock jumps 14%

It's revenue from operations for the quarter under review came in at Rs 185.45 crore, clocking a growth of 970.73 per cent YoY from Rs17.32 crore reported in Q1FY20

Sun Pharma launches cheapest favipiravir brand in India, at Rs 35 a pill

Pricing pressure in this category is already visible as Glenmark revised its original price (Rs 103 per tablet) to Rs 79 per tablet within a month of the launch

Will continue to focus on growing business faster than market: Sun Pharma

The company's strategy of developing the Specialty business as an additional growth engine has started delivering, with a gradual ramp up in specialty revenues, Shanghvi said

Weak US outlook, pricing pressures weigh on Sun Pharma's revenue growth

Margin gains in the June quarter unlikely to sustain

Sun Pharma posts surprise Rs 2,184 cr Q1 pre-tax loss on one-time expense

Firm's US revenue dips 33.5%; one-time loss of Rs 3,633 cr pertains to $213.3 mn pzayment by Taro, a Sun Pharma subsidiary, for settlement of anti-trust cases in the US

Sun Pharma Q1 net loss at Rs 1,655.6 cr, revenue down to Rs 7,585.3 cr

The company had posted a net profit of Rs 1,387.48 crore for the corresponding period of the previous fiscal, Sun Pharma said in a BSE filing

Top headlines: Maruti Suzuki Q1 results, loans under moratorium and more

Here are the top headlines of the day

Sun Pharma-owned subsidiary to acquire Canada's Aquinox Pharma for $8.2 mn

Indian company says no approvals are required for the acquisition and it is likely to be completed by July 31

Weekly stock picks by Religare Broking: Buy Godrej Consumer, Hero MotoCorp

Godrej Consumer's stock has been trading with a corrective bias for the last three weeks

Disclosure violations: Sun Pharma, top execs seek Sebi's consent settlement

Regulator initiates proceedings for disclosure violations

Top headlines: Mistry family in talks for funds, Google ups lending biz

Economic Affairs Secretary Tarun Bajaj says he is certain that a V-shaped economic recovery will take a year.

Sun Pharma's arm Taro Pharma resolves all cases with US Dept of Justice

Sun Pharma said its American arm Taro Pharmaceutical has resolved all cases involving multi-year investigations by US Department of Justice into the country's generic pharmaceutical industry

Sun Pharma up 4% as US arm's Taro Pharma resolves antitrust investigation

Taro Pharma has reached a settlement agreement with the US Department of Justice, Antitrust and Civil divisions to pay more than $200 million to settle the generic drug price fixing allegations

Sun Pharma aims for market share in all verticals amid Covid-19 situation

The drug major, which has presence in around 150 countries, caters to various various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others

Nifty outlook & stock calls by Anand Rathi: Buy Wipro, Sun Pharma

Wipro's stock has provided breakout from a symmetrical triangle formation on the daily chart with higher than average volumes

Sun Pharma to launch its first innovative product for psoriasis in Japan

Nod for Ilumya, a specialty product, would strengthen firm's dermatology portfolio in Japan, but analysts caution that the segment has been witnessing price erosion of late

Sun Pharma's diabetes NCE show promise; to go into phase 1 trials in Q3

The stock prices, however, dropped by 3.3 per cent on the BSE at the end of day's trade

Sun Pharma, Hikma ink pact for plaque psoriasis drug for MENA region

One of the company's wholly-owned subsidiaries and Hikma Pharmaceuticals have entered into the agreement for Ilumya, Sun Pharma said in a filing to BSE

Sun Pharma begins phase II clinical trial on dengue drug for Covid-19

This is the first phytopharmaceutical drug (plant based) that the country's drug regulator has approved for clinical trials for Covid-19.

Buy Sun Pharma June Futures at Rs 496: Nandish Shah of HDFC Securities

The stock's primary trend is positive and its price is trading above 200-day SMA